The Human Variable 

Here I apply CYNAERA’s analytical framework to the unlikely case of a consumer snack, Frito-Lay’s Baked Lay’s, as an emergent functional-nutrition platform for dysautonomia and MCAS patients. Using CYNAERA’s prevalence modeling (US-CCUC™, S³™, Pathos™, SymCas™, BRAGS™) and global market-behavior analytics, I examine how a legacy brand could reposition a common product into a precision-nutrition solution. A $3 billion opportunity in plain sight.

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

This white paper argues that MCS and MCAS are vantage points on a shared hypersensitivity terrain, proposing a new classification, Multi-Chemical and Environmental Hypersensitivity Disorders (MCEHD), that unites them, honors patient ingenuity, and formalizes my frameworks.

The CYNAERA ESA (Emergency Stabilization Authorization) framework presents a solution. During a declared emergency, ESA enables states and FEMA to pre-authorize qualified clinics to operate as temporary micro-ERs and reimburse those services as emergency protective measures. Critically, ESA does not require new legislation. It strategically aligns existing authorities under the Stafford Act for federal disaster declarations, FEMA Public Assistance Category B for emergency pro

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is profoundly sensitive to environmental stressors. Pollutants such as polycyclic aromatic hydrocarbons (PAHs), particulate matter (PM₂.₅, PM₁₀), nitrogen dioxide (NO₂), ground-level ozone (O₃), sulfur dioxide (SO₂), and volatile organic compounds (VOCs), combined with weather triggers like heat, cold, barometric pressure swings, mold, humidity, and pollen, drive flares that push patients into cycles of severe disabi

CYNAERA’s AI simulations analyze 120+ therapeutic candidates across 6 mechanisms, weighting them by patient endotype, Pathos™ severity score, and predicted remission probability. This map provides the first public-facing mechanism reference, while full dosing logic, contraindication overlays, and trial-ready protocols remain licensed.